Compare · CBLI vs MEDP
CBLI vs MEDP
Side-by-side comparison of Cleveland BioLabs, Inc. (CBLI) and Medpace Holdings Inc. (MEDP): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLI and MEDP operate in Biotechnology: Commercial Physical & Biological Resarch (Health Care), so they compete in similar markets.
- MEDP is the larger of the two at $17.55B, about 330.5x CBLI ($53.1M).
- MEDP has hit the wire 9 times in the past 4 weeks while CBLI has been quiet.
- MEDP has more recent analyst coverage (25 ratings vs 0 for CBLI).
- Company
- Cleveland BioLabs, Inc.
- Medpace Holdings Inc.
- Price
- -
- -
- Market cap
- $53.1M
- $17.55B
- 1M return
- -
- +0.58%
- 1Y return
- -
- +13.61%
- Industry
- Biotechnology: Commercial Physical & Biological Resarch
- Biotechnology: Commercial Physical & Biological Resarch
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2006
- 2016
- News (4w)
- 0
- 9
- Recent ratings
- 0
- 25
Medpace Holdings Inc.
Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It also provides clinical development services to the biotechnology, pharmaceutical, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. The company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.
Latest CBLI
- SEC Form 4: Barbarick Steve K was granted 60,000 shares
- SEC Form 4: Verny Lea was granted 60,000 shares
- SEC Form DEF 14A filed by Cleveland BioLabs, Inc.
- SEC Form 4: Markvicka Taunia was granted 100,000 shares
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Changes in Registrant’s Certifying Accountant, Financial Statements and Exhibits
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Cleveland BioLabs, Inc.
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Cytocom, Inc. Announces Plan to Adopt New Corporate Name "Statera BioPharma, Inc."
- Cleveland BioLabs, Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
Latest MEDP
- SEC Form 4 filed by Medpace Holdings Inc.
- SEC Form 4 filed by Medpace Holdings Inc.
- Director Mccarthy Cornelius P. Iii converted options into 28 shares, increasing direct ownership by 0.23% to 12,303 units (SEC Form 4)
- Director Kraft Robert O. converted options into 32 shares, increasing direct ownership by 3% to 987 units (SEC Form 4)
- Director Carley Brian T converted options into 36 shares, increasing direct ownership by 0.13% to 27,861 units (SEC Form 4)
- President & CEO Troendle August J. sold $30,320,929 worth of shares (48,667 units at $623.03), decreasing direct ownership by 13% to 338,225 units (SEC Form 4)
- UBS resumed coverage on Medpace with a new price target
- President & CEO Troendle August J. sold $1,589,941 worth of shares (2,564 units at $620.10), decreasing direct ownership by 0.66% to 386,892 units (SEC Form 4)
- Amendment: SEC Form SCHEDULE 13D/A filed by Medpace Holdings Inc.
- President & CEO Troendle August J. sold $27,403,895 worth of shares (43,916 units at $624.01), decreasing direct ownership by 10% to 389,456 units (SEC Form 4)